ADC Off Target Tox and Linker Stability
May 25, 2023
Antibody drug conjugates (ADCs) combine the benefits of both therapeutic monoclonal antibodies (mAb) and potent small molecule cytotoxic drugs. These moieties are connected through linkers that should be stable within systemic circulation, while maintaining the ability to cleave within the mAb-targeted cells to release highly specific payloads.
To propel your projects with The Power of Discovery.™
Contact Us Today
Let us know about your project!